Malaga Cove Capital LLC reduced its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 1.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,291 shares of the conglomerate’s stock after selling 48 shares during the quarter. Malaga Cove Capital LLC’s holdings in Danaher were worth $1,193,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter worth $25,000. nVerses Capital LLC purchased a new stake in shares of Danaher in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Danaher during the 2nd quarter valued at about $51,000. Financial Connections Group Inc. acquired a new position in Danaher during the second quarter worth about $51,000. Finally, Western Pacific Wealth Management LP purchased a new stake in shares of Danaher in the first quarter valued at about $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Danaher
In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 10.90% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on Danaher
Danaher Trading Down 0.9 %
NYSE:DHR opened at $247.81 on Thursday. Danaher Co. has a 12 month low of $192.35 and a 12 month high of $281.70. The business’s 50-day moving average is $265.79 and its two-hundred day moving average is $260.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $178.99 billion, a PE ratio of 47.29, a price-to-earnings-growth ratio of 4.55 and a beta of 0.85.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 earnings per share. Research analysts predict that Danaher Co. will post 7.51 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 2 Online Educational Platforms Staging a Turnaround
- How to Find Undervalued Stocks
- Top 3 Sectors Outperforming After Trump’s Victory
- What is a Death Cross in Stocks?
- Sono-Tek’s $2M Buyback: A Buying Opportunity in Clean Tech
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.